Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Phase NA Recruiting
15 enrolled
Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery
Phase NA Recruiting
80 enrolled
Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer
Phase 2 Recruiting
79 enrolled
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
Phase 2 Recruiting
46 enrolled
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
Phase 2 Recruiting
120 enrolled
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Phase 3 Recruiting
3,680 enrolled
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Phase 2 Recruiting
60 enrolled
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
Phase 1 Recruiting
50 enrolled
The Effect of Cold Salt Water Foot Bath on the Development Of Chemotherapy-Induced Peripheral Neuropathy
Phase NA Recruiting
30 enrolled
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
Phase 1/2 Recruiting
31 enrolled
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Phase 3 Recruiting
1,000 enrolled
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Phase 3 Recruiting
400 enrolled
OPERA-02
Phase 3 Recruiting
1,000 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
LUBRECA
Phase NA Recruiting
140 enrolled
PREACT
Phase NA Recruiting
66 enrolled
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Phase 3 Recruiting
364 enrolled
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
Phase 1 Recruiting
300 enrolled
DEBRA
Phase 3 Recruiting
1,670 enrolled
Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer
Phase NA Recruiting
300 enrolled
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
Phase 1 Recruiting
36 enrolled
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase 1 Recruiting
45 enrolled
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 Recruiting
399 enrolled
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Phase 1/2 Recruiting
768 enrolled
DELTA-101
Phase 1 Recruiting
396 enrolled
ANTARES
Phase 2 Recruiting
28 enrolled
JS207 Combination Therapy in Triple-negative Breast Cancer
Phase 2 Recruiting
80 enrolled
Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
Phase 2 Recruiting
768 enrolled
ALLIANCE
Phase NA Recruiting
174 enrolled
Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC
Phase NA Recruiting
33 enrolled
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Phase 1 Recruiting
86 enrolled
PREHAB-BC65
Phase NA Recruiting
90 enrolled
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase 2 Recruiting
285 enrolled
TAILOR RT
Phase 3 Recruiting
2,140 enrolled
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
Phase 2 Recruiting
50 enrolled
Study of INCB123667 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
604 enrolled
A Study of XMT-1660 in Participants With Solid Tumors
Phase 1 Recruiting
319 enrolled
Adjuvant WIDER
Phase 3 Recruiting
1,400 enrolled
EvoPAR-BR01
Phase 3 Recruiting
500 enrolled
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Phase 1 Recruiting
60 enrolled
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
Phase 3 Recruiting
446 enrolled
AIMSS-RPS
Phase 2 Recruiting
20 enrolled
PRETORIA
Phase NA Recruiting
250 enrolled
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Phase 2 Recruiting
36 enrolled
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Phase 1 Recruiting
51 enrolled
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Phase 2 Recruiting
40 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Phase 1 Recruiting
694 enrolled
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Phase 1/2 Recruiting
42 enrolled
ReRT
Phase NA Recruiting
1,800 enrolled